RecruitingPhase 4NCT07303816

Statins to Prevent Cancer Associated Blood Clots

STAT-CAT: Statin Therapy to Prevent Cancer Associated Venous Thromboembolism

Sponsor

Brigham and Women's Hospital

Enrollment

4,000 participants

Start Date

Jun 11, 2026

Study Type

INTERVENTIONAL

Conditions

Cancer Venous Thromboembolism Cardiovascular Events

Summary

Patients with cancer are at high risk for life-threatening venous thromboembolism (VTE) yet rarely receive anticoagulant prophylaxis due to bleeding risks. Thus, effective prophylaxis in oncology requires a method to reduce VTE without increasing hemorrhage. The primary aim of the Statin Therapy to Prevent Cancer Associated Venous Thromboembolism (STAT-CAT) trial is to test whether rosuvastatin 20 mg daily for 12 months compared to placebo can safely prevent VTE in patients with newly diagnosed or recently relapsed cancer who are at increased thrombotic risk, are not planned to be anticoagulated, and who do not otherwise take statin therapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Placebo Drug and a drug called Rosuvastatin for people with cancer, cardiovascular events, and other related conditions. The study is currently recruiting participants at 2 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRosuvastatin

Rosuvastatin is a statin drug that helps reduce cholesterol and can help reduce risks of blood clots. In this study, patients will take 20mg of Rosuvastatin (or placebo) for to 12 months.

DRUGPlacebo Drug

The placebo pills are pills with no medicine in them.